Ftse Mib
33.578,31
-0,38%
DAX
18.149,16
-0,07%
S&P 500
5.462,15
-0,13%
NASDAQ
17.766,72
0,28%
Bitcoin
61.650,76
-0,26%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Entrada Therapeutics Inc (TRDA) Entrada Therapeutics Inc (TRDA) Notizie

TRDA

Entrada Therapeutics (TRDA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TRDA
DataOraFonteTitoloSimboloCompagnia
24/06/202413:15GlobeNewswire Inc.Entrada Therapeutics Announces $100 Million Registered Direct OfferingNASDAQ:TRDAEntrada Therapeutics Inc
24/06/202412:00GlobeNewswire Inc.Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
14/06/202422:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
13/06/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRDAEntrada Therapeutics Inc
03/06/202413:00GlobeNewswire Inc.Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:TRDAEntrada Therapeutics Inc
16/05/202422:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
16/05/202413:00GlobeNewswire Inc.Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:TRDAEntrada Therapeutics Inc
07/05/202413:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TRDAEntrada Therapeutics Inc
07/05/202413:00GlobeNewswire Inc.Entrada Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
13/03/202412:00GlobeNewswire Inc.Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
07/02/202413:00GlobeNewswire Inc.Entrada Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TRDAEntrada Therapeutics Inc
03/01/202413:00GlobeNewswire Inc.Entrada Therapeutics Promotes Nathan J. Dowden to PresidentNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202317:56Dow Jones NewsEntrada Therapeutics Shares Tumble 27% After FDA Keeps Clinical HoldNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202313:54Dow Jones NewsEntrada: FDA Declines to Lift Hold on Duchenne StudyNASDAQ:TRDAEntrada Therapeutics Inc
22/11/202313:00GlobeNewswire Inc.Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
07/11/202313:00GlobeNewswire Inc.Entrada Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
29/09/202322:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TRDAEntrada Therapeutics Inc
21/09/202313:00GlobeNewswire Inc.Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
07/09/202313:00GlobeNewswire Inc.Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy CommunityNASDAQ:TRDAEntrada Therapeutics Inc
05/09/202322:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TRDAEntrada Therapeutics Inc
10/08/202313:00GlobeNewswire Inc.Entrada Therapeutics Appoints Gina Chapman to its Board of DirectorsNASDAQ:TRDAEntrada Therapeutics Inc
08/08/202313:25Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TRDAEntrada Therapeutics Inc
08/08/202313:23Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:TRDAEntrada Therapeutics Inc
08/08/202313:00GlobeNewswire Inc.Entrada Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:TRDAEntrada Therapeutics Inc
01/08/202313:00GlobeNewswire Inc.Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular DystrophyNASDAQ:TRDAEntrada Therapeutics Inc
22/06/202322:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TRDAEntrada Therapeutics Inc
22/06/202322:13Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:TRDAEntrada Therapeutics Inc
08/06/202323:12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TRDAEntrada Therapeutics Inc
06/06/202313:00GlobeNewswire Inc.Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceNASDAQ:TRDAEntrada Therapeutics Inc
10/05/202313:46Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TRDAEntrada Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TRDA

La tua Cronologia

LSE
RF90
Citi Fun 24
TG
17M
Moelis &
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network